

ORGAN MANUFACTURING

THE VISION TO A CURE WITH
AN UNLIMITED SUPPLY OF ORGANS

Martine Rothblatt, PhD

Chairman and Chief Executive Officer
United Therapeutics Corporation



SAFE HARBOR STATEMENT

Remarks today concerning

United Therapeutics may include forward-looking statements which represent United Therapeutics’ expectations or beliefs regarding future events. We caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in United Therapeutics’ periodic and other reports filed with the SEC.

There can be no assurance

that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. United Therapeutics assumes no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements.

This presentation

and any related discussions or statements are intended to educate investors about our company. Sometimes that process includes reporting on the progress and results of clinical trials or other developments with respect to our products. This presentation and any related discussions or statements are not intended to promote our products, to suggest that our products are safe and effective for any use other than what is consistent with their FDA-approved labeling, or to provide all available information regarding the products, their risks, or related clinical trial results. Anyone seeking information regarding the use of one of our products should consult the full prescribing information for the product available on our website at www.unither.com.

REMODULIN®, TYVASO®, and ORENITRAM® are registered trademarks of United Therapeutics Corporation.
Implantable System for Remodulin® (ISR), TYSUBERPROST™, are trademarks of United Therapeutics Corporation.
TreVyent® is a registered trademark of SteadyMed Ltd.



SCOPE OF THE PROBLEM




2 MAIN TECHNOLOGIES – EVLP AND REGEN





EVLP





WORLDWIDE EVLP PATIENTS TO DATE

1636 LIVES SAVED*

*Global figure including all EVLP technologies. To date, our EVLP clinical trial has successfully transplanted EVLP lungs into more than 50 patients.



UNITED THERAPEUTICS LUNG RECIPIENTS



HEATHER LEVERINGTON



20 months post double lung transplant, Heather won two gold medals at the 2018 US Transplant Games in Utah.




CHUCK BOETSCH



I did my first 5k in early May, and this was my second. I have also traveled to Colorado, up to 10,500 feet with no issues.





UT LUNG SERVICE MODEL






EX-VIVO ORGAN PERFUSION EXPANSION MODEL





LONGER TERM VISION DE NOVO LUNGS + CELLULARIZATION





DOUBLE / TRIPLE SUPPLY





3D BIO PRINTING


Organ
Manufacturing






REGENERATIVE MEDICINE

DECELLULARIZED



CELLULARIZED







THANK YOU